Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.

Opus Genetics, Inc.

Rocket Doctor AI ( ($TSE:AIDR) ) has shared an announcement. Rocket Doctor AI reported second-quarter 2026 revenue of $734,028, up 43% year over ye...

Rocket Doctor AI Accelerates U.S. Expansion as Revenue Jumps 43% in Q2

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Opus Genetics (IRD) and TScan Therapeutics (TCRX). Opus Genetics ...

Analysts Offer Insights on Healthcare Companies: Opus Genetics (IRD) and TScan Therapeutics (TCRX)

Top-rated BofA Securities analyst Ronald Epstein cut his price target on Rocket Lab ($RKLB) stock to $110 from $115 but kept a Buy rating. The anal...

Rocket Lab Stock (RKLB) Outlook: Top BofA Analyst Trims Target but Says Long-Term Upside Still Strong

In a report released yesterday, from Maxim Group maintained a Hold rating on Allbirds. The company’s shares closed yesterday at $2.54. The word on ...

Allbirds (BIRD) Gets a Hold from Maxim Group

Shares of space company Rocket Lab ($RKLB) are up in today’s trading even though five executives sold 78,843 shares worth a combined $5.49 million....

Rocket Lab Stock Rises Even as Insiders Sell $5.49 Million in Shares – Here’s What Investors Should Know

New activity is brewing for Iridium Communications ( ($IRDM) ). The company has submitted a Form DEFM14A to the SEC, indicating an upcoming shareho...

Iridium Sets Shareholder Vote on Rocket Lab Acquisition

The latest announcement is out from Rocket Doctor AI ( ($TSE:AIDR) ). Rocket Doctor AI Inc. has granted 24,000 stock options exercisable at $0.70 p...

Rocket Doctor AI Grants Equity Incentives to Consultants

Space company Rocket Lab ($RKLB) could reach positive adjusted EBITDA soon after a successful test launch of its Neutron rocket. CFO Adam Spice sai...

Rocket Lab Stock (RKLB): One Neutron Launch Could Change Its Entire Financial Picture

Rocket Doctor AI ( ($TSE:AIDR) ) has issued an update. Rocket Doctor AI has secured a strategic provider network agreement in California that opens...

Rocket Doctor AI Secures Broad Network Deal to Expand California Telehealth Access

Rocket Lab USA ($RKLB) is growing fast. In Q2, the company’s revenue jumped 62%, while its backlog reached $2.36 billion, showing strong demand for...

RKLB Stock Has 72 Risk Factors — Which Matter Most for Investors?

Investors betting on the space sector have a choice between SpaceX ($SPCX) and Rocket Lab ($RKLB), but the two stocks offer different opportunities...

Wall Street Sees Nearly 60% Upside for This Space Stock — And It Isn’t Rocket Lab

Rocket Doctor AI ( ($TSE:AIDR) ) has provided an announcement. Rocket Doctor AI Inc. has closed the second tranche of an oversubscribed private pla...

Rocket Doctor AI Raises C$3.26 Million in Oversubscribed Convertible Debenture Financing

Bird Construction (($TSE:BDT)) has held its Q2 earnings call. Read on for the main highlights of the call. Bird Construction’s latest earnings call...

Bird Construction Earnings Call Highlights Record Momentum

In a report released today, Ian Gillies from Stifel Nicolaus maintained a Buy rating on Bird Construction, with a price target of C$85.00. Accordin...

Stifel Nicolaus Sticks to Its Buy Rating for Bird Construction (BDT)

Rocket Lab ($RKLB) stock was down 2.2% on Tuesday at the time of writing, as the aerospace and launch services provider reported mixed second-quart...

Stifel Stays Bullish on Rocket Lab (RKLB) Stock Despite Mixed Q2 Results. Here’s Why

Rocket Lab ($RKLB) stock is down over 4% at the market open today after the company reported mixed Q2 2026 results. Investors grew cautious as Pete...

Cantor Fitzgerald Raises Rocket Lab Stock Price Target after Q2 Earnings, Calls Neutron ‘the Most Material Catalyst’

Piper Sandler analyst Biren Amin maintained a Buy rating on Opus Genetics today and set a price target of $11.00. According to TipRanks, Amin is a ...

Opus Genetics (IRD) Receives a Buy from Piper Sandler

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roivant Sciences (ROIV), Opus Genetics (IRD) and Reg...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Rocket Doctor AI ( ($TSE:AIDR) ) has provided an announcement. Rocket Doctor AI Inc., a Vancouver-based digital health and AI technology firm, prov...

Rocket Doctor AI Raises CAD $2.27 Million in Oversubscribed Debenture Financing to Fuel U.S. Expansion

Rocket Doctor AI ( ($TSE:AIDR) ) just unveiled an update. Rocket Doctor AI has engaged B2i Digital to provide investor-focused digital marketing ad...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRD	$4.46	-3.04%	568.50K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRD	$4.46	-3.0%	568.50K
3
4
5
6

IRD

Get Opus Genetics, Inc. Data in Excel

Get Opus Genetics, Inc. Data in Excel